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with chronic diseases or disability are characterised by
multiple pathology, non›specific presentations, a high
incidence of secondary complications, and the need
for intensive rehabilitation. They need a generalist
approach to assessment and treatment and are poorly
served by a superspecialist profession. Even doctors
who specialise in caring for elderly people often prefer
curing acute illnesses to using their skills in chronic
disease and rehabilitation.5
To combat age discrimination health professionals
and their institutions must acknowledge and docu›
ment it and then act to eradicate it. These actions need
to go on at all levels of the service, including hospital
departments and general practices. The General Medi›
cal Council, the royal colleges, and specialist associa›
tions can all guide their members through the process
and must recruit older users of the health service to
help them. The charity Age Concern continues to
lobby for legislation to outlaw age discrimination3 6 and
also campaigns for a government inquiry into ageist
practices in the NHS. Steps have already been taken to
redress the imbalance of research in older people. The
major research funding agencies now refuse to fund
trials with an arbitrary age limit for recruitment.
Longer term measures will begin at medical school,
where modern teaching methods can be used to foster
enthusiasm among medical students for older people
and their problems. Partnerships with older people will
enhance core teaching, as well as empower older
health service users to shape the curriculum. Later on,
all doctors could acquire the necessary skills by doing
six months in geriatric medicine during training.7
Reshaping the health service around older patients
need not be painful and can start now. Even small
adjustments to the ward, clinic, or surgery can make a
difference. For example, admission wards with access
to a breadth of expertise are better for patients with
multiple problems than direct admission to a specialist
(say orthopaedic) ward. Individual doctors can also
make a difference by seeking out and removing their
own prejudices. More sweeping changes will have to
follow, however, including: engaging older people in
the commissioning and design of services; accepting
that undergraduate and postgraduate training pro›
duces doctors whose aspirations don’t match the needs
of their patients; finding and protecting money to pay
for care of older people; returning to an emphasis on
rehabilitation and convalescence; and changing the
way we think. If the health service could be made fit for
older people, it would be fit for everybody.
But there is no escaping the conclusion that a
health service that will serve an ageing population well
will need substantially more money than is available
now. Older people probably bear the brunt of
rationing within the health service. Many of those who
fought in the second world war, rejoiced in the creation
of the welfare state, and paid for it throughout their
working lives now feel let down. Many are bitter that
the government has failed to produce any response to
Royal Commission on Long Term care for Elderly
People that was published in March. It recommended
that the personal care element of the package should
be free and funded by taxation. 8
There is still no consensus on where extra money
for the health service should come from, but Professor
Sir John Grimley Evans, a gerontologist from Oxford,
who closed the conference, said there should be no
further discussion of rationing until NHS funding is
brought in line with other comparable European
countries. The yearly average spend per head in the
UK is 25% lower than the European average. If the
government does not increase expenditure on the
NHS substantially and if the health professions do not
manage to counter ageism then the NHS may fail to
meet the challenge presented by an ageing society.
Alison Tonks assistant editor, BMJ
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Cardiac troponins in chest pain
Can help in risk stratification
Despite a fall in the age adjusted prevalence ofcardiovascular disease in the developedworld,1 the number of patients presenting with
chest pain is rising. Greater public awareness of the
importance of chest pain has lowered the threshold for
seeking medical help, while improvements in our abil›
ity to manage acute coronary syndromes necessitate
prompt and accurate identification of ischaemic
cardiac pain. Most patients who present to accident
and emergency departments will have non›cardiac
pain and others, with ischaemic pain, will be at low risk
of serious adverse events in the short term. In contrast,
many of those at high risk have no diagnostic clinical
or electrocardiographic findings at presentation (about
50% of patients ultimately diagnosed as having an
acute myocardial infarction, and 65% of those with
unstable angina, present with non›diagnostic electro›
cardiograms).2 The major challenge is therefore deter›
mining the risk of an individual patient.
There are two components to such risk. “Acute
risk” is determined by the volume and severity of
ischaemic myocardium (usually reflected in electro›
cardiographic changes) and the extent of myocardial
injury (indicated by troponins and cardiac enzymes).
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“Prognostic risk” is influenced by prior cardiac damage,
confounding risk factors (such as age, smoking,
diabetes, and hypertension), and the extent of under›
lying coronary artery disease (defined by stress testing,
perfusion scanning, or coronary angiography). Cur›
rently, neither form of risk is systematically evaluated.
Traditionally patients with suspected myocardial
ischaemia are admitted for “screening” tests to exclude
myocardial infarction, largely based on serial measure›
ments of markers for myocardial necrosis. Historically,
the markers used were non›specific enzymes released
from myocardial cells and other tissues such as skeletal
muscle and liver. Recently, however, extremely sensitive
and specific markers have become widely available—
the cardiac troponins.
Cardiac troponin I and troponin T are components
of the myocardial contractile apparatus. They are
encoded by distinct genes, allowing the development
of highly specific immunoassays.3 Unlike other cardiac
markers, the troponins are undetectable in healthy
subjects,3 so that even minor increases indicate
myocardial damage.
Concurrent with the increasing sensitivity of tests
for cardiac necrosis, it has become clear that classifying
patients with acute coronary syndromes into those
with unstable angina, non›Q wave infarction, and Q
wave infarction is limited in accuracy and validity. A
continuum of risk exists,4 but until recently the
enzymes measured were too insensitive to reflect this.
Cardiac troponins, however, provide an accurate meas›
ure of cardiac necrosis, and several large studies show
that the risk of death from an acute coronary
syndrome is directly related to values of troponin I or
T.5 6 Conversely, patients with no detectable troponins
have a good short term prognosis.7 8
The availability of such sensitive and specific mark›
ers imparts new opportunities. Instead of using blood
tests merely to confirm or refute a diagnosis of acute
myocardial infarction we can use cardiac troponins to
triage patients with chest pain. Patients with positive
values are at high risk of (re)infarction or death. They
also seem to benefit most from treatments such as low
molecular weight heparin and glycoprotein IIb/IIIa
antagonists,9 10 though this observation from retrospec›
tive analyses needs to be confirmed prospectively.
Likewise, it remains to be seen whether patients
positive for cardiac troponins are those most likely to
benefit from early coronary angiography and revascu›
larisation.
Patients without ST elevation and with negative
cardiac troponins six or more hours after the onset of
pain have an excellent short term prognosis, leading to
the suggestion that they might be discharged directly
from the emergency department.7 Such a strategy has
not, however, been tested prospectively. In the study by
Hamm et al most patients were admitted to hospital
and the favourable outcome among those with
negative troponins may have been influenced by the
treatment they received.7 Nevertheless, it seems that
stable patients with non›diagnostic electrocardiograms
and negative markers 6›8 hours after the onset of pain
need not remain in coronary care units.8 One
reasonable strategy may be to submit such patients to
early predischarge exercise testing, which provides
additional prognostic information reflecting the extent
and severity of underlying coronary artery disease.11
Though cardiac troponins are undoubtedly useful
in the risk stratification of patients with chest pain, they
do have limitations. They take several hours to rise,
peaking at 12›24 hours,4 so values on admission may
be misleading. In patients initially negative for
troponin a second assay should therefore be per›
formed 6›12 hours later. In addition, values remain
raised for up to 14 days,4 limiting their usefulness in
diagnosing reinfarction. A further limitation relates to
the standardisation of, particularly, troponin I assays,
which are produced by several manufacturers and may
give variable results, particularly at the lower end of
their range.3 Clinicians should therefore familiarise
themselves with the system and cut offs used locally.
Cardiac troponins provide limited diagnostic infor›
mation. Though a positive result will usually confirm
that chest pain is due to an acute coronary syndrome,
raised values are also found in pulmonary embolism,
cardiac failure, myocarditis, and renal failure.7 In all
cases, however, this seems to reflect subclinical myocar›
dial damage. Similarly, a negative cardiac troponin
result does not rule out angina or ischaemic heart dis›
ease. Coronary artery disease is present in at least a
third of patients with low risk clinical features and
negative serum troponin I values throughout the first
12 hours of admission.12 Thus, though their short term
prognosis seems to be excellent, patients with
suspected ischaemic heart disease despite negative tro›
ponins may require further investigation.
The assessment of patients with chest pain is a dif›
ficult skill, informed by clinical judgment. Cardiac tro›
ponins can, however, help in this process—not merely
in the application of diagnostic labels but as a means to
estimate risk and guide management.
Graham S Hillis specialist registrar in cardiology
Keith A A Fox professor of cardiology
Royal Infirmary of Edinburgh, Edinburgh EH3 9YW
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